Cargando…

Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study

AIM: The aim of the present study was to assess the safety and effectiveness of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients undergoing electrical cardioversion (EC). METHODS: A propensity score-matched analysis was per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rago, Anna, Pezzullo, Enrica, Malvezzi Caracciolo d’Aquino, Marco, Scognamiglio, Gabriella, Caso, Valentina Maria, Martone, Francesco, Attena, Emilio, Parisi, Valentina, D’Onofrio, Antonio, Golino, Paolo, Nigro, Gerardo, Russo, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187032/ https://www.ncbi.nlm.nih.gov/pubmed/34113202 http://dx.doi.org/10.2147/JBM.S299265

Ejemplares similares

Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score–Matched Study
por: Rago, Anna, et al.
Publicado: (2020)

Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study
por: Russo, Vincenzo, et al.
Publicado: (2020)

Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octagenarians with atrial fibrillation
por: Carbone, Andreina, et al.
Publicado: (2022)

Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response
por: Rago, Anna, et al.
Publicado: (2023)

Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study
por: Russo, Vincenzo, et al.
Publicado: (2019)

Safety of Transesophageal Echocardiogram in Anticoagulated Patients
por: Natale, Francesco, et al.
Publicado: (2023)

Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry
por: Papp, Judit, et al.
Publicado: (2017)

Cardioversion of Atrial Arrhythmias: Audit of Anticoagulation Management
por: Mayet, Jamil, et al.
Publicado: (1997)

Corrigendum to: Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry
Publicado: (2018)

Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion
por: Warden, Bruce A., et al.
Publicado: (2018)

Periprocedural anticoagulation in atrial fibrillation: Update on electrical cardioversion and ablation
por: van Vugt, S. P. G., et al.
Publicado: (2018)

Anticoagulation in Atrial Fibrillation Cardioversion: What Is Crucial to Take into Account
por: Lucà, Fabiana, et al.
Publicado: (2021)

Chronic Oral Anticoagulation and Clinical Outcome in Hospitalized COVID-19 Patients
por: Russo, Vincenzo, et al.
Publicado: (2021)

Advances in Percutaneous Patent Foramen Ovale Closure: From the Procedure to the Echocardiographic Guidance
por: Sperlongano, Simona, et al.
Publicado: (2022)

Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation
por: Russo, Vincenzo, et al.
Publicado: (2020)

Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis
por: Merino, Jose L, et al.
Publicado: (2019)

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion
por: Coppola, Giuseppe, et al.
Publicado: (2019)

Are Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?
por: Naydenov, Stefan, et al.
Publicado: (2021)

The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator
por: Russo, Vincenzo, et al.
Publicado: (2020)

Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures
por: Finks, Shannon W., et al.
Publicado: (2018)

Do we always need anticoagulation before cardioversion of atrial fibrillation in ladies?
por: Görenek, Bülent, et al.
Publicado: (2016)

Racial and Sex Disparities in Anticoagulation After Electrical Cardioversion for Atrial Fibrillation and Flutter
por: Mentias, Amgad, et al.
Publicado: (2021)

Inappropriate shocks due to air entrapment in patients with subcutaneous implantable cardioverter‐defibrillator: A meta‐summary of case reports
por: Iavarone, Michele, et al.
Publicado: (2022)

Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis
por: Shin, Dong Geum, et al.
Publicado: (2015)

Comparing the delay with different anticoagulants before elective electrical cardioversion for atrial fibrillation/flutter
por: Wall, Christopher, et al.
Publicado: (2019)

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
por: Ezekowitz, Michael D, et al.
Publicado: (2018)

Electrical cardioversion
por: Sucu, Murat, et al.
Publicado: (2009)

Electrogenic Cardioversion
por: Theodore, Joseph, et al.
Publicado: (2014)

Device-Related Complications and Inappropriate Therapies Among Subcutaneous vs. Transvenous Implantable Defibrillator Recipients: Insight Monaldi Rhythm Registry
por: Russo, Vincenzo, et al.
Publicado: (2022)

Findings of transoesophageal echocardiogram in appropriately anticoagulated patients with persistent atrial fibrillation prior to planned cardioversion
por: Barysienė, Jūratė, et al.
Publicado: (2017)

Nursing Teleconsultation for the Outpatient Management of Patients with Cardiovascular Disease during COVID-19 Pandemic
por: Russo, Vincenzo, et al.
Publicado: (2021)

Trends and Outcomes of Oral Anticoagulation With Direct Current Cardioversion for Atrial Fibrillation/Flutter at an Academic Medical Center
por: Arshad, Samiullah, et al.
Publicado: (2022)

Single-Chamber Leadless Cardiac Pacemaker in Patients Without Atrial Fibrillation: Findings From Campania Leadless Registry
por: Russo, Vincenzo, et al.
Publicado: (2022)

The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy
por: Caso, Valentina Maria, et al.
Publicado: (2022)

Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched Analysis
por: Fiedler, Lukas, et al.
Publicado: (2021)

SAFETY AND EFFICACY OF SAME-DAY ELECTIVE CORONARY ANGIOGRAPHY AND SYNCHRONIZED CARDIOVERSION IN PATIENTS WITH ATRIAL FIBRILLATION WITH UNINTERRUPTED ANTICOAGULATION
por: Gallen, Rory, et al.
Publicado: (2021)

Remote monitoring of implantable loop recorders reduces time to diagnosis in patients with unexplained syncope: a multicenter propensity score-matched study
por: Russo, Vincenzo, et al.
Publicado: (2023)

COVID-19 and Heart: From Clinical Features to Pharmacological Implications
por: Russo, Vincenzo, et al.
Publicado: (2020)

Clinical Outcome of Hospitalized COVID-19 Patients with History of Atrial Fibrillation
por: Russo, Vincenzo, et al.
Publicado: (2022)

Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience
por: Attena, Emilio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eo5tfls13dpd765oeq0grqil68